KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) FCF Margin: 2009-2025

Historic FCF Margin for Alnylam Pharmaceuticals (ALNY) over the last 14 years, with Sep 2025 value amounting to 25.06%.

  • Alnylam Pharmaceuticals' FCF Margin rose 1717.00% to 25.06% in Q3 2025 from the same period last year, while for Sep 2025 it was 8.37%, marking a year-over-year increase of 760.00%. This contributed to the annual value of -1.89% for FY2024, which is 419.00% down from last year.
  • Alnylam Pharmaceuticals' FCF Margin amounted to 25.06% in Q3 2025, which was up 39.03% from 18.02% recorded in Q2 2025.
  • In the past 5 years, Alnylam Pharmaceuticals' FCF Margin registered a high of 45.61% during Q3 2023, and its lowest value of -424.28% during Q1 2025.
  • Its 3-year average for FCF Margin is -39.72%, with a median of -10.26% in 2023.
  • Per our database at Business Quant, Alnylam Pharmaceuticals' FCF Margin skyrocketed by 12,479bps in 2021 and then crashed by 40,517bps in 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' FCF Margin (Quarterly) stood at -66.54% in 2021, then skyrocketed by 2,069bps to -45.85% in 2022, then soared by 3,559bps to -10.26% in 2023, then tumbled by 723bps to -17.49% in 2024, then soared by 1,717bps to 25.06% in 2025.
  • Its FCF Margin stands at 25.06% for Q3 2025, versus 18.02% for Q2 2025 and -424.28% for Q1 2025.